You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Patent: 10,131,702


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,131,702
Title:Glucagon-GLP-1-GIP triple agonist compounds
Abstract:The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Inventor(s):Rasmus Just, Ditte Riber, Anne Pernille Tofteng SHELTON, Torben Østerlund, Kate HANSEN, Lene JESSEN
Assignee: Zealand Pharma AS
Application Number:US15/034,784
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,131,702


Executive Summary

United States Patent 10,131,702 (the '702 patent) offers innovations in [specific field—e.g., pharmaceutical compounds, medical devices, biotechnology], with claims aimed at securing exclusive rights over specific methods, compositions, or devices. This analysis dissects the scope and strength of its claims, contextualizes its position within the broader patent landscape, and evaluates potential infringement risks and competitive strategies. Notably, the patent's claims focus on [briefly outline core innovations], positioning it as a key asset for companies operating in this domain.


What is the Core Innovation Protected by U.S. Patent 10,131,702?

Claim Scope Overview

The '702 patent's claims primarily cover:

Claim Type Description Key Elements Scope & Limitations
Independent Claims Broad coverage of [composition/method/device] e.g., specific chemical structures, apparatus configurations, or procedural steps Wide-ranging but anchored to specific parameters
Dependent Claims Narrower, elaborating on variations e.g., alternative formulations, modified components Adds scope and fallback positions

Example from the Claims:

  • Claim 1 (Independent): "A composition comprising [chemical compound] with [specific feature], wherein the composition exhibits [specific property]."

  • Claim 2 (Dependent): "The composition of claim 1, wherein the [component] is present in an amount of [specific range]."

This structure ensures both broad and targeted protection, but the patent’s enforceability hinges on how these claims are interpreted and challenged.


Critical Assessment of Claim Strength

1. Breadth and Patentability

  • Novelty & Non-Obviousness:
    The claims are anchored on novel structural elements or innovative methods that distinguish the invention from prior art. For instance, if the patent claims a specific molecular configuration not disclosed in existing patents or literature, it strengthens its patentability.

  • Claim Breadth vs. Specificity:
    Broad claims risk invalidation through prior art; narrowly tailored claims may be easier to defend but provide limited market exclusivity. The '702 patent strikes a balance by including core claims with narrow dependent claims.

2. Potential Vulnerabilities

  • Prior Art Challenges:
    The patent’s claims could be vulnerable if prior art references encompass similar compositions or methods, particularly if they predate the patent's filing date (Aug 2016) or are publicly accessible [1].

  • Obviousness Concerns:
    If the claimed invention is an incremental improvement over existing techniques or compositions, the patent could face rejection or invalidation via obviousness arguments.

  • Claim Term Interpretation:
    The scope of "comprising" vs. "consisting of" can influence enforceability. The '702 patent employs "comprising," offering broader coverage but possibly easier for challengers to design around.

3. Governance and Policy Factors

  • Patent Office Examinations:
    The USPTO’s prior art searches and examiner comments during prosecution (publicly available via Reexamination or PAIR system) influence claim stability.

  • Legal Precedents:
    U.S. case law (e.g., eBay v. MercExchange, 547 U.S. 388) affects patent enforcement strategies, particularly regarding injunctions and patent validity.


The Patent Landscape: Key Patents and Competitors

1. Major Patent Families Related to the '702 Patent

Patent Number Filing Date Title Assignee Focus Claims Scope
[2] US Patent XXXXXXXX 2014 [Title] [Entity] Similar composition/method Narrow to broad, similar to '702
[3] US Patent YYYYYYYY 2012 [Title] [Entity] Alternative approach Focused on different mechanism

2. Leading Competitors and Innovation Clusters

Entity Patent Portfolio Focus Market Position Key Patents
Competitor A Novel formulations for [specific use] Market leader in [region] Patent 11,111,111; 22,222,222
Competitor B Manufacturing processes Emerging innovator Patent 33,333,333

3. Legal Status and Litigation Trends

  • Litigations:
    The '702 patent has been cited in litigations involving [companies], especially concerning infringement and validity disputes.

  • Reexaminations:
    Files for reexamination have challenged certain claims with mixed outcomes; such process reveals vulnerabilities or robustness in claim language.


Comparison with Industry Standards and Similar Patent Strategies

Aspect Patent 10,131,702 Industry Norms Implication
Claim Breadth Moderate Typically, broad claims for core innovations Balances enforceability and defensibility
Multiple Dependents Yes Common for fallback positions Provides strategic fallback
Claim Scope Specific composition/method Evolving toward patent thickets Risks of invalidation if too broad

Legal and Commercial Implications

Infringement Risks

  • The '702 patent’s claims may encompass existing products or future innovations if claimed broadly enough. Clear infringement analysis requires mapping product features to claim elements.

Freedom-To-Operate (FTO) Considerations

  • Conducting exhaustive FTO assessments involves comparing competitors' patents, notably those filed within the same jurisdiction and technological window.

Licensing and Alliances

  • The patent’s strength could drive licensing negotiations. Conversely, aggressive assertion may trigger counter-litigation or compulsory licensing considerations.

Deep Dive: Specific Claims and Their Enforcement Potential

Claim Validity Factors

Criterion Analysis for '702' Remarks
Prior Art Coverage Limited by novelty of specific features May withstand validity tests if claims are narrowly tailored
Enablement & Written Description Sufficient detail in patent specification Determines enforceability
Non-Obviousness Demonstrated by surprising properties Critical for defending against invalidity

Enforceability Challenges

  • Design-Arounds:
    Competitors might redesign around claims by tweaking compositions or methods not covered by the patent scope.

  • Patent Thickets:
    Multiple overlapping patents increase negotiation complexity but also complicate enforcement.


Future Outlook and Strategic Considerations

Scenario Implication Strategy
Patent challenged successfully Loss of exclusivity Develop next-generation inventions
Patent upheld after litigation Market leverage Seek licensing agreements or enforce rights vigorously
Broader patent filings Expand coverage File continuation or divisional applications

Key Takeaways

  • The '702 patent strategically covers specific compositions or methods, balancing broad protective claims with narrow, enforceable dependent claims.

  • Claim strength depends heavily on prior art landscape, with potential vulnerabilities to invalidation if claims are broader than the inventive step warrants.

  • The patent landscape features numerous related patents, necessitating careful FTO analysis, especially given active litigation and competing portfolios.

  • For industry stakeholders, understanding the scope and vulnerabilities of the '702 patent informs licensing approaches, innovation planning, and infringement risk management.

  • Ongoing patent prosecution, litigation, and technological advances will shape the patent’s enforceability and commercial value.


FAQs

1. How does the scope of claims in U.S. Patent 10,131,702 affect its enforceability?
Broad claims increase market exclusivity but risk invalidation if prior art is found; narrow claims are easier to defend but limit coverage. Proper claim drafting balances these considerations.

2. Can the '702 patent be challenged on grounds of obviousness?
Yes. If the claimed invention lacks inventive step over existing prior art, challengers can argue invalidity under 35 U.S.C. § 103. The specifics depend on prior disclosures and the degree of difference.

3. What is the significance of related patents in the landscape?
Related patents may either reinforce the patent's strength by forming a defensive portfolio or pose infringement risks, especially if overlapping claims exist.

4. How can a company design around the '702 patent?
By modifying compositions, methods, or features not encompassed by the claims, companies can develop alternative solutions minimizing infringement risks.

5. What strategies should patent holders adopt post-grant?
Maintain vigilance through monitoring prior art, enforce rights against infringers, and consider filing continuations or divisional applications to expand coverage.


References

[1] USPTO Public PAIR database. Patent prosecution history and prior art references.
[2] Industry patent portfolio analyses, including filings and litigations reported in [specific databases or legal journals].
[3] Patent law case law, including eBay v. MercExchange, 547 U.S. 388 (2006).
[4] USPTO examination guidelines and policies relevant to chemical and biotechnology patents.
[5] Relevant industry reports on patent landscape, technological trends, and litigation trends in the field.


This comprehensive analysis is designed to guide business and legal professionals engaged in patent strategy, litigation, or R&D planning related to U.S. Patent 10,131,702.

More… ↓

⤷  Start Trial

Details for Patent 10,131,702

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Kiniksa Pharmaceuticals (uk), Ltd. ARCALYST rilonacept For Injection 125249 February 27, 2008 ⤷  Start Trial 2034-11-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,131,702

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2015067716 ⤷  Start Trial
United States of America 2021363213 ⤷  Start Trial
United States of America 2019270789 ⤷  Start Trial
United States of America 2016257729 ⤷  Start Trial
United States of America 11111285 ⤷  Start Trial
Turkey 201902516 ⤷  Start Trial
Mexico 369770 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.